Shattuck Labs, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Taylor H. Schreiber
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 West 5th Street Austin TX United States of America 78703
- IPO Date
- Oct 9, 2020
- CIK
- 0001680367
- Website
- shattucklabs.com
- Similar Companies
- Business
- Shattuck Labs, Inc. Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company that develops novel antibodies targeting tumor necrosis factor (TNF) receptors for the treatment of inflammatory and immune-mediated diseases, including inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis. The company offers a pipeline centered on death receptor 3 (DR3) antagonists, with lead candidate SL-325, a potentially first-in-class monoclonal antibody designed for high-affinity binding, epitope specificity, and Fc-silencing to achieve complete blockade of the clinically validated TL1A/DR3 pathway; SL-425, an extended half-life DR3 antagonist advancing through IND-enabling studies for IBD; and preclinical bispecific antibodies combining DR3 with undisclosed targets for broader autoimmune indications. Founded in 2016 and headquartered in Austin, Texas, with additional operations in Durham, North Carolina, Shattuck Labs focuses on protein engineering expertise to address unmet needs in immunology and inflammation through specialized therapeutics that modulate immune responses on key cell types driving disease pathology. In August 2025, the company completed a $103 million private placement financing led by OrbiMed Advisors, with participation from other institutional investors, extending its cash runway into 2029 to support advancement of SL-325 through Phase 1 trials in healthy volunteers—following FDA clearance of its IND application—and into upcoming placebo-controlled Phase 2 studies in IBD patients; this transaction coincided with a strategic repositioning as an immunology-focused organization, including Board refreshments with new directors Daniel Baker, M.D., and Mona Ashiya, Ph.D., alongside the exit of four prior members to streamline governance for pipeline execution.
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $11.00 Average PT from Brokerages
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs, Inc. Announces Proposed Public Offering
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Why Is Shattuck Labs Stock Trading Lower On Monday?
Shattuck Labs Announces Phase 1 Results for SL-325
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Aberdeen Group plc Buys 436,673 Shares of Shattuck Labs, Inc. $STTK
Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.50
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Consensus PT from Analysts
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
Shattuck Labs, Inc. (NASDAQ:STTK) Sees Large Growth in Short Interest
Why Shattuck Labs Stock Soared in December
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy